TXG vs WST: fair value comparison
10x Genomics, Inc. and West Pharmaceutical Services, Inc. · Updated 2026-10-19
TXG has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, TXG currently ranks higher by quality score.
| TXG | WST | |
|---|---|---|
| Verdict | No estimate yet | Fairly valued |
| Last price | $69.86 | $366.00 |
| 12-month range | $12.44–$97.74 | $230.95–$384.02 |
| Rank by discount to fair value | — | #60 of 108 Healthcare |
| Rank by quality score | #45 of 301 Healthcare | #46 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: TXG fair value analysis · WST fair value analysis